[English]  [Pусский]  [中文]  
 
ctt-journal > Kaplanov K.2 et al. (Abstract)

Kaplanov K.2 et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract14

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Bortezomib-containing regimes in the treatment of multiple myeloma complicated by renal failure

Kamil D. Kaplanov, Ludmila S. Tregubova, Tatiana U. Klitochenko, Irina V. Matveeva, Anna L. Shipaeva

GUZ "Volgograd Regional Clinical Oncology Dispensary N1", Department of Hematology, Volgograd, Russia

Correspondence: Kamil D. Kaplanov, GUZ "Volgograd Regional Clinical Oncology Dispensary N1", Department of Hematology, Zemliachky str., 78, Volgograd, 400138, Russia, E-mail: kamilos@spam is badmail.ru

Abstract

Aim: To evaluate the effectiveness of bortezomib-containing regimes in the treatment of multiple myeloma (MM) complicated by renal failure.

Methods: Between January 2006 and December 2010 a total of 24 MM patients with renal failure were treated. Sixteen (67%) and 8 (33%) patients received bortezomib-containing regimes as part of their first and second line therapy respectively. In the first line 12 (75%) of the 16 patients were treated with a program of V-MP (bortezomib, Alkeran, prednisone), and 4 (25%) patients were treated with a program of PAD (bortezomib, Adriablastin, high-dose dexamethasone). In the second line 5 patients (63%) received V-MP, and 3 (37%) received the PAD program.

The median serum creatinine level for the entire group was 311 mcmol/l (range, 170–1504). There were mostly elderly patients with high levels of β2-microglobulin and C-reactive protein in the subgroup who received bortezomib-containing regimes in first-line (p<0.05).

Results: Seven of 24 (29%), and 11 (46%) patients achieved a complete remission (CR) and very good partial remission (VGPR) respectively. The median of serum creatinine decreased from 311 mcmol/l to 120 mcmol/l. The frequency of CR and VGPR was higher in the subgroup that received bortezomib-containing first-line therapy (p <0.05). The two-year survival freedom from progression in the whole group was 20%, and 4-year overall survival was 39%. The differences between the subgroups didn’t have a statistically significant character (p>0.05).

Conclusions: Bortezomib-containing regimes are feasible in MM nephropathy and effective in the first and second lines of treatment, but when considering indicators of remission they are more effective in the primary patients.

Keywords: multiple myeloma, bortezomib, nephropathy, renal failure, chemotherapy